Physician

Mudusar I Raza, M.D.

According to 2025 Medicare claims, Mudusar Raza, M.D. (NPI: 1467562371) practices pulmonary disease in the Hagerstown-Martinsburg, MD-WV market, with the plurality of this provider's patient population coming from Washington, MD. This provider's primary affiliated billing organization is MEDICAL PRACTICES OF ANTIETAM, LLC (NPI: 1558430843; TIN: 522315129) and primary practice location at 21742-2940.

Raza's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,343 traditional Medicare patients, billed 5,808 HCPCS/CPT codes, and received $360,536 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,824 prescription claims across 508 beneficiaries totaling $989,170 in drug costs, led by Trelegy Ellipta (Fluticasone/Umeclidin/Vilanter). DME data shows 3,586 claims. Open Payments data shows 62 records totaling $1,530. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $20,608 to $360,536. Similarly, Part D prescription costs have moved sharply higher in recent years, from $15,155 to $989,170. For DME billing, reported payments moved sharply higher in recent years, from $229 to $105,074.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	70	208	$20,608
2016	550	2,504	$217,816
2017	356	1,069	$107,167
2018	251	741	$87,194
2019	286	785	$110,039
2020	316	841	$115,676
2021	278	855	$120,951
2022	1,249	3,127	$277,708
2023	1,388	4,370	$358,441
2024	1,343	5,808	$360,536

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	24	97	$15,155
2016	30	94	$26,952
2017	N/R	30	$8,530
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	329	1,053	$368,677
2023	453	2,524	$1,039,446
2024	508	2,824	$989,170

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	67	$3,383
2017	N/R	42	$1,999
2018	N/R	25	$858
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	389	673	$33,235
2023	1,191	3,123	$115,316
2024	1,334	3,586	$116,185

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	963	1,520	$94
94729	Test to examine how well the lungs exchange gases	335	338	$44
94727	Test to determine lung volumes using gas dilution or washout	336	339	$35
94060	Test to measure expiratory airflow and volume changes before and after medication administration	337	342	$30
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	863	1,354	$13

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	427	17,490	$362,061
Breztri Aerosphere	Budesonide/Glycopyr/Formoterol	191	9,030	$182,099
Ofev	Nintedanib Esylate	12	360	$117,305
Breo Ellipta	Fluticasone/Vilanterol	87	4,230	$52,917
Spiriva Respimat	Tiotropium Bromide	58	2,754	$46,753

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
E0601	Continuous positive airway pressure (cpap) device	Y	105	624	$17,722
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	35	215	$14,358
A7030	Full face mask used with positive airway pressure device, each	N	90	155	$12,562
J7626	Budesonide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, up to 0.5 mg	N	43	150	$9,439
A7031	Face mask interface, replacement for full face mask, each	N	64	149	$8,260

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	62	$1,530	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Mudusar I. Raza, M.D.?

Tedicare shows public-source Medicare data for Mudusar I. Raza, M.D. (NPI 1467562371), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Mudusar I. Raza, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Mudusar I. Raza, M.D.?

Mudusar I. Raza, M.D. is linked to MEDICAL PRACTICES OF ANTIETAM, LLC (billing NPI 1558430843) in the available physician profile data.

Does Mudusar I. Raza, M.D. have Open Payments data?

Mudusar I. Raza, M.D. has 62 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.